How to Register an Indian Pharmaceutical Product in Your Country: An Overview

In most countries, pharmaceutical products must be registered with the national regulatory authority before they can legally be imported and sold. This requirement applies regardless of where the product was manufactured — including India. Product registration is the regulatory authority's confirmation that the product meets safety, quality, and (where applicable) efficacy standards for the local market.

This post provides a general overview of the registration process. For country-specific regulatory requirements, you must engage a qualified regulatory affairs professional in your country — the process varies significantly across jurisdictions, and regulatory advice must be market-specific.

---

Why Registration Is Required

Pharmaceutical product registration serves several purposes:

1. Quality assurance: The regulatory authority reviews the manufacturer's GMP status and product quality data before allowing import 2. Market control: Authorities maintain visibility of what pharmaceutical products are available in their market 3. Patient safety: Registration processes (varying by country) may review safety data relevant to the product 4. Traceability: Registered products can be tracked and recalled if quality issues are identified

---

The General Registration Process

While specifics vary by country, most pharmaceutical import registration processes follow a broadly similar structure:

Step 1: Regulatory Landscape Assessment

Before initiating registration, determine: - Is the product registered or registerable in your country? - What risk classification does your country assign to this product type? - What dossier format does your regulatory authority require (CTD, ACTD, national format)? - Are there specific requirements for this therapeutic category? - What are the processing fees and timeline expectations?

This assessment requires a qualified regulatory professional in your country.

Step 2: Obtain Source Documentation from India

Registration submissions require documentation from India, including:

| Document | Source | |---------|--------| | Free Sale Certificate (FSC) / Certificate of Pharmaceutical Product (WHO CPP format) | CDSCO or State FDA in India | | Manufacturer's GMP certificate | CDSCO (WHO-GMP) or EU/US equivalent | | Certificate of Analysis (batch-specific, or representative batch) | Manufacturer | | Product composition / formula details | Manufacturer | | Stability data (per ICH Q1A) | Manufacturer | | Bioequivalence data (for certain generic registrations) | Manufacturer or published literature | | Manufacturing site information | Manufacturer |

Obtaining this documentation from the manufacturer — via your Indian supplier — can take time. Build this into your registration timeline.

Step 3: Prepare the Registration Dossier

Most regulatory authorities use the Common Technical Document (CTD) format (developed by ICH) or a regional variant such as the ASEAN Common Technical Document (ACTD) for Southeast Asian countries.

The CTD structure: - Module 1: Administrative (country-specific forms, application fee, FSC, product labelling for the local market) - Module 2: Summaries of quality, non-clinical, and clinical data - Module 3: Quality (manufacture, specifications, stability) - Module 4: Non-clinical (for generics, may rely on published data or reference product data) - Module 5: Clinical (for generics, typically bioequivalence study report)

For generic medicines, Module 5 typically requires a bioequivalence (BE) study demonstrating that the generic is bioequivalent to the reference product approved in your country (or an internationally recognised reference market). Some countries waive BE requirements for certain dosage forms (solutions, certain topicals) based on a BCS (Biopharmaceutical Classification System) waiver.

Step 4: Submit and Track

Submit the dossier to the regulatory authority with applicable fees. Processing times vary enormously: - Streamlined processes (countries with recognition of WHO PQ or stringent authority approvals): months - Standard dossier review processes: 1–3 years in many developing-country markets - Complex products / high-scrutiny authorities: longer

Maintain communication with your regulatory consultant and the authority to track status and respond to queries.

Step 5: Post-Registration Obligations

Registration is not a one-time event. Typical post-registration obligations include: - Periodic renewal (many registrations have a fixed validity period — 3–5 years commonly) - Notification or approval for manufacturing site changes, formulation changes, or specification changes - Post-marketing surveillance / pharmacovigilance reporting

---

Engaging a Local Regulatory Consultant

For all of the above, a qualified regulatory affairs (RA) professional in your importing country is essential. They will: - Know your country's specific requirements and current processing timelines - Advise on dossier completeness before submission (avoiding rejections) - Manage authority interactions on your behalf - Keep you informed of regulatory changes that affect your registered products

Your Indian supplier can provide the source documentation; your local RA consultant does the jurisdiction-specific work.

---